|1.||Pickup, Stephen: 3 articles (03/2009 - 08/2004)|
|2.||Toi, Masakazu: 2 articles (07/2015 - 05/2014)|
|3.||Hurvitz, Sara A: 2 articles (07/2015 - 07/2014)|
|4.||Taran, Tetiana: 2 articles (07/2015 - 05/2014)|
|5.||Shen, Kunwei: 2 articles (07/2015 - 05/2014)|
|6.||Masuda, Norikazu: 2 articles (01/2015 - 05/2014)|
|7.||Jerusalem, Guy: 2 articles (05/2014 - 01/2014)|
|8.||Zhou, Rong: 2 articles (01/2007 - 08/2004)|
|9.||Glickson, Jerry D: 2 articles (01/2007 - 08/2004)|
|10.||Lindsay, Mary-Ann: 1 article (07/2015)|
|1.||Breast Neoplasms (Breast Cancer)
11/01/2012 - "The two randomized trials (BOLERO-2 and TAMRAD) evaluating everolimus±endocrine therapy in a selected subgroup of HR-positive metastatic breast cancer patients have demonstrated a significant improvement in progression free survival for the combination compared to the endocrine therapy alone. "
06/01/2014 - "[BOLERO -- another remarkable step in treatment of breast cancer]."
07/01/2014 - "These preclinical data support the findings of the BOLERO 3 trial that shows that targeting of the PI3K/mTOR pathway in combination with trastuzumab is beneficial in trastuzumab-resistant breast cancer."
04/01/2012 - "Based on these promising results, everolimus is currently under evaluation in a series of phase III Breast Cancer Trials of Oral Everolimus (BOLERO) trials of women with HER2-positive and estrogen receptor-positive breast cancer. "
05/01/2014 - "Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial."
09/01/1989 - "In this study we report that uptake of 45calcium(45Ca) by neonate rat brain synaptosomes was disrupted during benthiocarb poisoning. "
07/01/1989 - "Decreased activities of Mg2+ and Ca2+-ATPases suggests impairment in energy synthesis and utilization processes in developing CNS of rat during benthiocarb poisoning. "
01/01/2014 - "In the primary comparison (PFS analysis based on the local review of disease progression from BOLERO-2 with the data from the other studies), everolimus plus exemestane appeared to be more efficacious than both fulvestrant 250 mg (HR = 0.47; 95 % credible interval [CrI] 0.38-0.58) and 500 mg (HR = 0.59; 95 % CrI 0.45-0.77). "
|4.||Primitive Neuroectodermal Tumors (PNET)
|5.||Hypertension (High Blood Pressure)